Stock VKTX VIKING THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Viking Therapeutics, Inc.

Equities

VKTX

US92686J1060

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-24 pm EDT 		5-day change 1st Jan Change
65.07 USD +0.22% Intraday chart for Viking Therapeutics, Inc. -4.24% +249.65%
Apr. 12 Health Care Falls as Risk Aversion Weighs on Obesity Drug Makers -- Health Care Roundup DJ
Apr. 02 Health Care Down on Flight From Risk -- Health Care Roundup DJ

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
6 Stocks Positioned to Soar as Investors Focus on MASH
AQ
Viking Therapeutics to Report Financial Results for First Quarter 2024 on April 24, 2024
PR
Health Care Falls as Risk Aversion Weighs on Obesity Drug Makers -- Health Care Roundup
DJ
Health Care Down on Flight From Risk -- Health Care Roundup
DJ
Health Care Down as Obesity-Drug Optimism Fades -- Health Care Roundup
DJ
Oppenheimer Adjusts Viking Therapeutics Price Target to $138 From $116, Maintains Outperform Rating
MT
Health Care Climbs on Weight-Loss Drug Excitement -- Health Care Roundup
DJ
Sector Update: Health Care Stocks Rise Tuesday Afternoon
MT
Sector Update: Health Care
MT
Stifel Adjusts Viking Therapeutics Price Target to $95 From $80, Maintains Buy Rating
MT
Viking Therapeutics Share Rise After Reporting 'Positive Results' in Study of Potential Obesity Drug
MT
Sector Update: Health Care Stocks Steady Premarket Tuesday
MT
Sector Update: Health Care
MT
Viking Therapeutics Reports 'Positive Results' in Study of Potential Obesity Drug; Shares Jump
MT
PE firm Olympus to sell 9.8% stake in India's Aster DM Healthcare for up to $234.5 million, term sheet shows
RE
Transcript : Viking Therapeutics, Inc. - Special Call
Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735
PR
Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735
CI
BTIG Raises Price Target on Viking Therapeutics to $100 From $86, Keeps Buy Rating
MT
Viking Therapeutics Announces $632.5 Million Public Offering Of Common Stock
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. VKTX Stock
  4. News Viking Therapeutics, Inc.